Revenue
2024
2025
Evommune, Inc. (EVMN)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| Research & development | $74.0M | $64.2M |
| Operating expenses | $94.1M | $77.0M |
| Operating income | −$81.1M | −$70.0M |
| EBITDAderived | −$80.5M | −$69.5M |
| Net income | −$68.9M | −$66.8M |
| Basic EPSper diluted share | -$11.22 | -$45.29 |
| Diluted EPSper diluted share | -$11.22 | -$45.29 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Patel Jeegar PravinkumarChief Scientific Officer | SellCommon Stock | 1.5K | $22.50 | $33.5K | 46.4K |
| Jun 22, 2026Form 4 · 10b5-1 | Drew Janice SuzannChief of Dev. Operations | SellCommon Stock | 20.0K | $22.63 | $452.6K | 67.8K |
| Jun 22, 2026Form 4 · 10b5-1 | Pena Luis C.President & CEO | SellCommon Stock | 7.4K | $22.71 | $168.9K | 630.5K |
| Jun 2, 2026Form 4 · 10b5-1 | Cohen David EDirector | SellCommon Stock | 600 | $21.38 | $12.8K | 17.6K |
| Jun 2, 2026Form 4 · 10b5-1 | Cohen David EDirector | SellCommon Stock | 5.5K | $20.21 | $110.3K | 18.2K |